<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044222</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308B301</org_study_id>
    <nct_id>NCT04044222</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of the Sintilimab Plus ICE Regimen Versus ICE Regimen in the Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed the First-line Standard Chemotherapy</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of the Sintilimab Plus ICE Regimen Versus Placebo Plus ICE Regimen in the Classic Hodgkin's Lymphoma Patients With First-line Standard Chemotherapy Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial studies the side effects of sintilimab and to see how well it works when
      given together with ifosfamide, carboplatin, and etoposide in treating patients with classic
      Hodgkin lymphoma that does not respond to first-line standard chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      randomized, double-blind, two arms , multicenter
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>44months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Classic Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment (placebo, etoposide, ifosfamide, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (placebo, etoposide, ifosfamide, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (placebo, etoposide, ifosfamide, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (placebo, etoposide, ifosfamide, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (placebo, etoposide, ifosfamide, carboplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who sign the informed consent form.

          2. Patients must have histopathologically confirmed cHL.

          3. Patients must have not respond to the first-line standard combination chemotherapy.

          4. Patients must have one measurable lesion (Lugano2014).

          5. Eastern Cooperative Oncology Group (ECOG) of 0-1.

          6. Male or female aged â‰¥18 years.

          7. Patients must have adequate organ and bone marrow function.

        Exclusion Criteria:

          1. Patients must not have known central nervous system (CNS) involvement.

          2. Patients must not have had prior exposure to any immune checkpoint inhibitors
             including anti-PD-L1 gents, anti-PD-L2 agents, or anti-CTLA-4 monoclonal antibodies.

          3. Patients must not have participate in another interventional clinical study at the
             same time.

          4. Patients must not be currently receiving any other investigational agents within 4
             weeks of study registration.

          5. Patients must not have received any other form of immunosuppressive therapy within 4
             weeks prior to the first dose of the study.

          6. Patients must not have received live attenuated vaccines within 4 weeks prior to the
             first dose (or plan to receive live attenuated vaccines during the study period).

          7. Patients with known immunodeficiency are ineligible .

          8. Patients with known active TB (Bacillus tuberculosis) are not eligible.

          9. Patients must not have had prior allogeneic stem cell transplantation or allogeneic
             organ transplantation.

         10. Patients must not be pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ronghua Zhang</last_name>
    <phone>15267110561</phone>
    <email>ronghua.zhang@innoventbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Zhou</last_name>
    <phone>86-021-31837200</phone>
    <email>hui.zhou@innoventbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital Chinese academy of Medical sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi</last_name>
      <phone>010-87788293</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

